Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor

Intravenous arketamine for treatment-resistant depression: open-label pilot study

(2020) Gustavo C. Leal et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Connecting With Patients—The Missing Links

(2020) Lisa Sanders et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Current status of potential therapeutic candidates for the COVID-19 crisis

(2020) Jiancheng Zhang et al.   BRAIN BEHAVIOR AND IMMUNITY

Nervous system involvement after infection with COVID-19 and other coronaviruses

(2020) Yeshun Wu et al.   BRAIN BEHAVIOR AND IMMUNITY

Consider Adjunctive Ketamine in Mechanically Ventilated COVID-19 Patients

(2020) Jamel Ortoleva   JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA

A SARS-CoV-2 protein interaction map reveals targets for drug repurposing

(2020) David E. Gordon et al.   NATURE

Convalescent serum lines up as first-choice treatment for coronavirus

(2020) Cormac Sheridan   NATURE BIOTECHNOLOGY

Neuropathogenesis and Neurologic Manifestations of the Coronaviruses in the Age of Coronavirus Disease 2019

(2020) Adeel S. Zubair et al.   JAMA Neurology

Molecular mechanisms of the rapid-acting and long-lasting antidepressant actions of (R)-ketamine

(2020) Kenji Hashimoto   BIOCHEMICAL PHARMACOLOGY

Poor-sleep is associated with slow recovery from lymphopenia and an increased need for ICU care in hospitalized patients with COVID-19: A retrospective cohort study

(2020) Jiancheng Zhang et al.   BRAIN BEHAVIOR AND IMMUNITY

Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention

(2020) Kenji Hashimoto   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Reissuing the sigma receptors for SARS-CoV-2

(2020) Umit Haluk Yesilkaya et al.   JOURNAL OF CLINICAL NEUROSCIENCE

Neurological associations of COVID-19

(2020) Mark A Ellul et al.   LANCET NEUROLOGY

Crosstalk between endoplasmic reticulum stress and anti-viral activities: A novel therapeutic target for COVID-19

(2020) Aditi Banerjee et al.   LIFE SCIENCES

In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication

(2020) Franck Touret et al.   Scientific Reports

Pathological Aspects of COVID-19 as a Conformational Disease and the Use of Pharmacological Chaperones as a Potential Therapeutic Strategy

(2020) Tomohiko Aoe   Frontiers in Pharmacology

Knocking Out Sigma-1 Receptors Reveals Diverse Health Problems

(2020) Simon Couly et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Recent progress of antiviral therapy for coronavirus disease 2019

(2020) Mengmeng Zhao et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Endoplasmic reticulum as a potential therapeutic target for covid-19 infection management?

(2020) Antoni Sureda et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Bi-phasic dose response in the preclinical and clinical developments of sigma-1 receptor ligands for the treatment of neurodegenerative disorders

(2020) Tangui Maurice   Expert Opinion on Drug Discovery

Why do SARS-CoV-2 NSPs rush to the ER?

(2020) Maryline Santerre et al.   JOURNAL OF NEUROLOGY

COVID‐19 drug repurposing: A review of computational screening methods, clinical trials, and protein interaction assays

(2020) Xueqing Wang et al.   MEDICINAL RESEARCH REVIEWS

Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms

(2020) David E. Gordon et al.   SCIENCE

Mechanisms of SARS-CoV-2 transmission and pathogenesis

(2020) Andrew G. Harrison et al.   TRENDS IN IMMUNOLOGY

Prenatal exposure to viral infection and neuropsychiatric disorders in offspring: A review of the literature and recommendations for the COVID-19 pandemic

(2020) Anna Zimmer et al.   BRAIN BEHAVIOR AND IMMUNITY

COVID-19 Infection—Preventing Clinical Deterioration

(2020) Christopher W. Seymour et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19

(2020) Eric J. Lenze et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Ketamine in COVID‐19 patients: Thinking out of the box

(2020) Karolina Akinosoglou et al.   JOURNAL OF MEDICAL VIROLOGY

Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis

(2019) Dorian A. Rosen et al.   Science Translational Medicine

Rapid‐acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective

(2019) Kenji Hashimoto   PSYCHIATRY AND CLINICAL NEUROSCIENCES

The Molecular Function of σ Receptors: Past, Present, and Future

(2019) Hayden R. Schmidt et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Non-canonical Targets Mediating the Action of Drugs of Abuse: Cocaine at the Sigma-1 Receptor as an Example

(2019) Tsung-Ping Su   Frontiers in Neuroscience

Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms

(2018) Panos Zanos et al.   PHARMACOLOGICAL REVIEWS

An update on ketamine and its two enantiomers as rapid-acting antidepressants

(2018) Kai Zhang et al.   Expert Review of Neurotherapeutics

Identification of the gene that codes for the σ2receptor

(2017) Assaf Alon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Serum Interleukin-6 Is a Predictive Biomarker for Ketamine’s Antidepressant Effect in Treatment-Resistant Patients With Major Depression

(2015) Jian-jun Yang et al.   BIOLOGICAL PSYCHIATRY

Activation of sigma-1 receptor chaperone in the treatment of neuropsychiatric diseases and its clinical implication

(2015) Kenji Hashimoto   JOURNAL OF PHARMACOLOGICAL SCIENCES

Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells

(2014) Tamaki Ishima et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Phase II Trial of the Sigma-1 Receptor Agonist Cutamesine (SA4503) for Recovery Enhancement After Acute Ischemic Stroke

(2014) Roman Urfer et al.   STROKE

Add-on fluvoxamine treatment for schizophrenia: an updated meta-analysis of randomized controlled trials

(2013) Taro Kishi et al.   EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE

Optimal Extent of Dopamine D2 Receptor Occupancy by Antipsychotics for Treatment of Dopamine Supersensitivity Psychosis and Late-Onset Psychosis

(2013) Masaomi Iyo et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Old drug ifenprodil, new hope for PTSD with a history of childhood abuse

(2013) Kenji Hashimoto et al.   PSYCHOPHARMACOLOGY

Ifenprodil for the Treatment of Flashbacks in Adolescent Female Posttraumatic Stress Disorder Patients with a History of Abuse

(2013) Tsuyoshi Sasaki et al.   PSYCHOTHERAPY AND PSYCHOSOMATICS

Sigma-1 Receptor Agonists as Therapeutic Drugs for Cognitive Impairment in Neuropsychiatric Diseases

(2012) Tomihisa Niitsu et al.   CURRENT PHARMACEUTICAL DESIGN

A Randomized, Double-Blind, Placebo-Controlled Trial of Fluvoxamine in Patients With Schizophrenia

(2012) Tomihisa Niitsu et al.   JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY

Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth in PC12 Cells by Ifenprodil: The Role of Sigma-1 and IP3 Receptors

(2012) Tamaki Ishima et al.   PLoS One

Sigma-1 receptor chaperone and brain-derived neurotrophic factor: Emerging links between cardiovascular disease and depression

(2012) Kenji Hashimoto   PROGRESS IN NEUROBIOLOGY

Ifenprodil for the Treatment of Flashbacks in Female Posttraumatic Stress Disorder Patients with a History of Childhood Sexual Abuse

(2011) Akira Kishimoto et al.   BIOLOGICAL PSYCHIATRY

The sigma-1 receptor enhances brain plasticity and functional recovery after experimental stroke

(2011) Karsten Ruscher et al.   BRAIN

Evaluation of sigma (σ) receptors in the antidepressant-like effects of ketamine in vitro and in vivo

(2011) Matthew J. Robson et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Targeting ligand-operated chaperone sigma-1 receptors in the treatment of neuropsychiatric disorders

(2011) Teruo Hayashi et al.   EXPERT OPINION ON THERAPEUTIC TARGETS

Taming the Ketamine Tiger

(2010) Edward F. Domino   ANESTHESIOLOGY

Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered

(2010) Ian Hindmarch et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Fluvoxamine improved cognitive impairments in a patient with schizophrenia

(2010) Tomihisa Niitsu et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases

(2010) Tsutomu Furuse et al.   Annals of General Psychiatry

Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors

(2009) Shinsui Kunitachi et al.   BRAIN RESEARCH

High occupancy of σ1 receptors in the human brain after single oral administration of donepezil: a positron emission tomography study using [11C]SA4503

(2009) Masatomo Ishikawa et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Despite irreversible binding, PET tracer [11C]-SA5845 is suitable for imaging of drug competition at sigma receptors—The cases of ketamine and haloperidol

(2008) Rudie Kortekaas et al.   NEUROCHEMISTRY INTERNATIONAL

Potentiation of Nerve Growth Factor-Induced Neurite Outgrowth by Fluvoxamine: Role of Sigma-1 Receptors, IP3 Receptors and Cellular Signaling Pathways

(2008) Tomoko Nishimura et al.   PLoS One

Potentiation of nerve growth factor-induced neurite outgrowth in PC12 cells by donepezil: Role of sigma-1 receptors and IP3 receptors

(2008) Tamaki Ishima et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Fluvoxamine as a sigma-1 receptor agonist improved cognitive impairments in a patient with schizophrenia

(2008) Masaomi Iyo et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY